Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection: Results from a Population-Based Study in Costa Rica

Raphael P. Viscidi, Mark Schiffman, Allan Hildesheim, Rolando Herrero, Philip E. Castle, Maria C. Bratti, Ana Cecilia Rodriguez, Mark E. Sherman, Sophia Wang, Barbara Clayman, Robert D. Burk

Research output: Contribution to journalArticle

159 Scopus citations

Abstract

Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.

Original languageEnglish (US)
Pages (from-to)324-327
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number2
DOIs
StatePublished - Feb 2004

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this